Results 271 to 280 of about 331,825 (303)
Some of the next articles are maybe not open access.
International Urogynecology Journal and Pelvic Floor Dysfunction, 1999
Bladder cancer is seen mainly in men. The incidence in women is increasing, but is still approximately three to four times lower than in men. In particular transitional cell cancers seem relatively more common in men then in women (ratio 4:1), but non-transitional cell cancer is also more frequent in men (ratio 2.7: 1).
Poel, H.G. van der +2 more
openaire +3 more sources
Bladder cancer is seen mainly in men. The incidence in women is increasing, but is still approximately three to four times lower than in men. In particular transitional cell cancers seem relatively more common in men then in women (ratio 4:1), but non-transitional cell cancer is also more frequent in men (ratio 2.7: 1).
Poel, H.G. van der +2 more
openaire +3 more sources
Current Problems in Cancer, 1990
Bladder cancer is largely a preventable disease; epidemiologic studies indicate that the majority of cases occur as a result of cigarette smoking or occupational exposures. The impact of screening high-risk populations is uncertain, but prompt and early diagnosis is essential for optimal therapeutic results.
openaire +4 more sources
Bladder cancer is largely a preventable disease; epidemiologic studies indicate that the majority of cases occur as a result of cigarette smoking or occupational exposures. The impact of screening high-risk populations is uncertain, but prompt and early diagnosis is essential for optimal therapeutic results.
openaire +4 more sources
European Urology, 2008
Patients with bladder cancer face a variable risk of recurrence based on their clinical characteristics and the biology of their disease. Physicians need tools to accurately estimate the risk of recurrence and cancer-specific mortality to recommend individualized therapy and to design appropriate clinical trials.A MEDLINE literature search was ...
Shariat Shahrokh F. +4 more
openaire +2 more sources
Patients with bladder cancer face a variable risk of recurrence based on their clinical characteristics and the biology of their disease. Physicians need tools to accurately estimate the risk of recurrence and cancer-specific mortality to recommend individualized therapy and to design appropriate clinical trials.A MEDLINE literature search was ...
Shariat Shahrokh F. +4 more
openaire +2 more sources
Lipomatosis of the bladder presenting as bladder cancer
International Journal of Urology, 2003Abstract A case of bladder lipomatosis in an 81‐year‐old man is presented. The preoperative diagnosis was bladder tumor. A transurethral resection of the bladder was performed and a pathological examination revealed lipomatosis of the bladder. This entity is extremely rare and, to our knowledge, this is the second case reported in the English published
Ozden, Tulunay +4 more
openaire +2 more sources
Bladder cancer: oligometastases and imaging
Nature Reviews Urology, 2017The term oligometastases was introduced to describe patients with limited metastatic disease in whom treatment might result in long-term disease-free survival or even cure. Imaging is pivotal for identification of these patients. The definition of oligometastatic bladder cancer and the optimal imaging modalities for diagnosis and response prediction ...
Mertens, Laura S, Horenblas, Simon
openaire +4 more sources
Hematology/Oncology Clinics of North America, 1992
The majority of patients with bladder cancer have superficial disease. Occupational exposure to metabolites of aniline dyes and other aromatic amines has been associated with the development of bladder cancer. Latency periods can reach 50 years. Cigarette smoking has also been strongly linked to bladder cancer as an etiologic factor.
K A, Itoku, B S, Stein
openaire +2 more sources
The majority of patients with bladder cancer have superficial disease. Occupational exposure to metabolites of aniline dyes and other aromatic amines has been associated with the development of bladder cancer. Latency periods can reach 50 years. Cigarette smoking has also been strongly linked to bladder cancer as an etiologic factor.
K A, Itoku, B S, Stein
openaire +2 more sources
JAAPA
Abstract: Bladder cancer, the 10th most common cancer globally, primarily manifests as urothelial cell carcinoma. Risk factors involve acquired genetic mutations and congenital predispositions, impacting diagnosis and management. This article discusses the risk factors, clinical presentation, and treatment strategies, with emphasis on ...
+7 more sources
Abstract: Bladder cancer, the 10th most common cancer globally, primarily manifests as urothelial cell carcinoma. Risk factors involve acquired genetic mutations and congenital predispositions, impacting diagnosis and management. This article discusses the risk factors, clinical presentation, and treatment strategies, with emphasis on ...
+7 more sources
Current Opinion in Oncology, 1992
In the search for sensitive and specific tumor markers for bladder carcinoma, expression of various oncogenes and gene products (such as c-erb B-2, p53) and epidermal growth factor receptor merits particular attention. Although the results are not yet conclusive, important predictive markers are about to emerge from ongoing studies in this field ...
openaire +6 more sources
In the search for sensitive and specific tumor markers for bladder carcinoma, expression of various oncogenes and gene products (such as c-erb B-2, p53) and epidermal growth factor receptor merits particular attention. Although the results are not yet conclusive, important predictive markers are about to emerge from ongoing studies in this field ...
openaire +6 more sources
Expert Opinion on Pharmacotherapy, 2007
Gemcitabine, a deoxycytidine analogue, is an inhibitor of DNA synthesis. With myelosupression being its most serious toxicity, gemcitabine has, however, a favourable toxicity profile. It was tested in urothelial bladder cancer at different stages of the disease.
Fadi, El Karak, Aude, Flechon
openaire +2 more sources
Gemcitabine, a deoxycytidine analogue, is an inhibitor of DNA synthesis. With myelosupression being its most serious toxicity, gemcitabine has, however, a favourable toxicity profile. It was tested in urothelial bladder cancer at different stages of the disease.
Fadi, El Karak, Aude, Flechon
openaire +2 more sources
Current Urology Reports, 2018
Bladder cancer (BC) is the second most common genitourinary malignancy, with a growing population of survivors globally. Over the past two decades, there has been a growing awareness of not only the oncologic, but also the quality of life ramifications of a BC diagnosis, treatment, and surveillance. In the current review, the literature surrounding the
openaire +2 more sources
Bladder cancer (BC) is the second most common genitourinary malignancy, with a growing population of survivors globally. Over the past two decades, there has been a growing awareness of not only the oncologic, but also the quality of life ramifications of a BC diagnosis, treatment, and surveillance. In the current review, the literature surrounding the
openaire +2 more sources